A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Study sponsor: Replimune, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2030-01Estimated
Enrollment · participants280Estimated
Source updated2026-04-02Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.